Article    Table of Contents                    Full Text of this article    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Jasmer, R. M.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial

Robert M. Jasmer, MD; Jussi J. Saukkonen, MD; Henry M. Blumberg, MD; Charles L. Daley, MD; John Bernardo, MD; Eric Vittinghoff, PhD; Mark D. King, MD; L. Masae Kawamura, MD; Philip C. Hopewell, MD, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators*

15 October 2002 | Volume 137 Issue 8 | Pages 640-647

Background: Rifampin and pyrazinamide are recommended for treatment of latent tuberculosis infection in adults without HIV infection, but reports of severe hepatotoxicity have raised concerns about its safety. Clinical trials have not compared this treatment with isoniazid in adults without HIV infection.

Objective: To compare the safety and tolerance of a 2-month regimen of rifampin and pyrazinamide with that of a 6-month regimen of isoniazid for treatment of latent tuberculosis infection.

Design: Multicenter, prospective, open-label trial.

Setting: Three urban public health tuberculosis clinics in the United States.

Patients: 589 adults with latent tuberculosis infection who met U.S. criteria for treatment.

Intervention: Patients were assigned in alternate weeks to receive rifampin and pyrazinamide daily for 2 months (n = 307) or isoniazid daily for 6 months (n = 282).

Measurements: Primary end points were hepatotoxicity, other adverse events, and percentage of patients who completed treatment.

Results: Sixteen of 207 (7.7%) patients assigned to rifampin and pyrazinamide developed grade 3 or 4 hepatotoxicity compared with 2 of 204 (1%) patients assigned to isoniazid (odds ratio, 8.46 [95% CI, 1.9 to 76.5]; P = 0.001). The rifampin plus pyrazinamide regimen was more likely than the isoniazid regimen to be discontinued because of hepatotoxicity (odds ratio, 5.19; P = 0.033). The overall percentage of nonhepatotoxic adverse events was 20% in the rifampin–pyrazinamide group and 16% in the isoniazid group. The proportion of patients who completed the study treatment was 61% and 57%, respectively.

Conclusions: A 2-month regimen of rifampin and pyrazinamide was associated with an increased risk for grade 3 or 4 hepatotoxicity compared with a 6-month regimen of isoniazid. Liver enzymes should be measured routinely during treatment to screen for liver injury and prevent progression to severe toxicity.

*For a list of the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators, see the Appendix.

Editors' Notes Context Guidelines from the American Thoracic Society and Centers for Disease Control and Prevention for treating latent tuberculosis infection advocate 2 months of rifampin plus pyrazinamide as an effective alternative to 6 to 9 months of isoniazid or 4 months of rifampin. However, case reports have described severe liver injury in patients who were receiving the 2-month regimen. Contribution This nonrandomized, open-label trial found that the risk for grade 3 or 4 liver injury was higher in patients taking 2 months of rifampin plus pyrazinamide (7.7%) than in patients taking 6 months of isoniazid (1%). Clinical Implications If clinicians use the short-course regimen, they should vigilantly follow patients' liver enzyme levels. –The Editors

 

Author and Article Information

From San Francisco General Hospital Medical Center, University of California, San Francisco, and Francis J. Curry National Tuberculosis Center, San Francisco, California; Boston University School of Medicine, Boston, Massachusetts; and Emory University School of Medicine and Grady Memorial Hospital, Atlanta, Georgia.

Grant Support: By the National Institutes of Health (AI 01549, HL 62977, HL 03035, HL 03078, and HL 03057) and the Emory Medical Care Foundation.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Robert M. Jasmer, MD, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, Room 5K-1, 1001 Potrero Avenue, San Francisco, CA 94110; e-mail, rjasmer{at}itsa.ucsf.edu.

Current Author Addresses: Drs. Jasmer, Daley, and Hopewell: Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, Room 5K-1, 1001 Potrero Avenue, San Francisco, CA 94110.

Drs. Saukkonen and Bernardo: Division of Pulmonary and Critical Care Medicine, Boston University School of Medicine, 80 East Concord Street, Room 304, Boston, MA 02118.

Drs. Blumberg and King: Division of Infectious Diseases, Emory University, 69 Butler Street, Atlanta, GA 30303.

Dr. Vittinghoff: Department of Epidemiology and Biostatistics, University of California, San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105.

Dr. Kawamura: Department of Public Health, Tuberculosis Control Section, 1001 Potrero Avenue, Building 90, Room WD94, San Francisco, CA 94110.

Author Contributions: Conception and design: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, M.D. King, P.C. Hopewell.

Analysis and interpretation of the data: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, J. Bernardo, E. Vittinghoff, P.C. Hopewell.

Drafting of the article: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, E. Vittinghoff, M.D. King, P.C. Hopewell.

Critical revision of the article for important intellectual content: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, E. Vittinghoff, M.D. King, L.M. Kawamura, P.C. Hopewell.

Final approval of the article: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, E. Vittinghoff, M.D. King, L.M. Kawamura, P.C. Hopewell.

Provision of study materials or patients: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, C.L. Daley, J. Bernardo, M.D. King, L.M. Kawamura.

Statistical expertise: R.M. Jasmer, E. Vittinghoff.

Obtaining of funding: R.M. Jasmer, H.M. Blumberg, M.D. King, P.C. Hopewell.

Administrative, technical, or logistic support: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, J. Bernardo, M.D. King, L.M. Kawamura, P.C. Hopewell.

Collection and assembly of data: R.M. Jasmer, J.J. Saukkonen, H.M. Blumberg, J. Bernardo, M.D. King.

Related articles in Annals:

Editorials
Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores
Leonard E. Braitman AND Paul R. Rosenbaum

Annals 2002 137: 693-695. [Full Text]  

Summaries for Patients
Short-Course Treatment for Latent Tuberculosis Is Associated with More Frequent Liver Injury Than Long-Course Treatment Is

Annals 2002 137: I-32. [Full Text]  

This article has been cited by other articles:

				D. Menzies, R. Long, A. Trajman, M.-J. Dion, J. Yang, H. Al Jahdali, Z. Memish, K. Khan, M. Gardam, V. Hoeppner, et al. Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial Ann Intern Med, November 18, 2008; 149(10): 689 - 697. [Abstract] [Full Text] [PDF]

				H. M. Blumberg Needed: New and Better Tools to Combat Latent Tuberculosis Infection Ann Intern Med, November 18, 2008; 149(10): 761 - 763. [Full Text] [PDF]

				J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]

				K. R. Page, F. Sifakis, R. Montes de Oca, W. A. Cronin, M. C. Doherty, L. Federline, S. Bur, T. Walsh, W. Karney, J. Milman, et al. Improved Adherence and Less Toxicity With Rifampin vs Isoniazid for Treatment of Latent Tuberculosis: A Retrospective Study. Arch Intern Med, September 25, 2006; 166(17): 1863 - 1870. [Abstract] [Full Text] [PDF]

				M. Schechter, R. Zajdenverg, G. Falco, G. L. Barnes, J. C. Faulhaber, J. S. Coberly, R. D. Moore, and R. E. Chaisson Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 922 - 926. [Abstract] [Full Text] [PDF]

				British Thoracic Society Standards of Care Committ BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment Thorax, October 1, 2005; 60(10): 800 - 805. [Abstract] [Full Text] [PDF]

				A. B. Younossian, T. Rochat, J-P. Ketterer, J. Wacker, and J-P. Janssens High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis Eur. Respir. J., September 1, 2005; 26(3): 462 - 464. [Abstract] [Full Text] [PDF]

				F. F. Fountain, E. Tolley, C. R. Chrisman, and T. H. Self Isoniazid Hepatotoxicity Associated With Treatment of Latent Tuberculosis Infection: A 7-Year Evaluation From a Public Health Tuberculosis Clinic Chest, July 1, 2005; 128(1): 116 - 123. [Abstract] [Full Text] [PDF]

				H. M. Blumberg, M. K. Leonard Jr, and R. M. Jasmer Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection JAMA, June 8, 2005; 293(22): 2776 - 2784. [Abstract] [Full Text] [PDF]

				M. N. Lobato, R. R. Reves, R. M. Jasmer, J. C. Grabau, N. N. Bock, N. Shang, and for the 2RZ Study Group Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons Chest, April 1, 2005; 127(4): 1296 - 1303. [Abstract] [Full Text] [PDF]

				D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]

				A. Mohan, S. K. Sharma, D. Menzies, and D. Yee Side Effects of Antituberculosis Drugs Am. J. Respir. Crit. Care Med., April 1, 2004; 169(7): 882 - 883. [Full Text] [PDF]

				C. C. Leung, W. S. Law, K. C. Chang, C. M. Tam, W. W. Yew, C. K. Chan, and M. Y. Wong Initial Experience on Rifampin and Pyrazinamide vs Isoniazid in the Treatment of Latent Tuberculosis Infection Among Patients With Silicosis in Hong Kong Chest, December 1, 2003; 124(6): 2112 - 2118. [Abstract] [Full Text] [PDF]

				E. Weir and D. N. Fisman Latent tuberculosis: revised treatment guidelines Can. Med. Assoc. J., October 28, 2003; 169(9): 937 - 938. [Full Text]

				P. A. LoBue and K. S. Moser Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 443 - 447. [Abstract] [Full Text] [PDF]

				R. E. Chaisson Tuberculosis Chemotherapy: Still a Double-edged Sword Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1461 - 1462. [Full Text] [PDF]

				D. Yee, C. Valiquette, M. Pelletier, I. Parisien, I. Rocher, and D. Menzies Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis Am. J. Respir. Crit. Care Med., June 1, 2003; 167(11): 1472 - 1477. [Abstract] [Full Text] [PDF]

				R. M. Jasmer and C. L. Daley Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection: Is It Safe? Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 809 - 810. [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				K. Khan, P. Muennig, M. Behta, and J. G. Zivin Global Drug-Resistance Patterns and the Management of Latent Tuberculosis Infection in Immigrants to the United States N. Engl. J. Med., December 5, 2002; 347(23): 1850 - 1859. [Abstract] [Full Text] [PDF]

				R. M. Jasmer, P. Nahid, and P. C. Hopewell Latent Tuberculosis Infection N. Engl. J. Med., December 5, 2002; 347(23): 1860 - 1866. [Full Text] [PDF]

				Shorter Regimens Not Necessarily Better for Latent TB Journal Watch (General), November 8, 2002; 2002(1108): 2 - 2. [Full Text]

				L. E. Braitman and P. R. Rosenbaum Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores Ann Intern Med, October 15, 2002; 137(8): 693 - 695. [Full Text] [PDF]